Akebia Therapeutics Inc

For the period ended Mar 31, 2025. Filed May 8, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 8, 2025

AKBA$0.54+1.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)

	Three Months Ended March 31,
(dollars in thousands, except per share amounts)	2025	2024
Revenues
Product revenue, net	$55,791	$31,009
License, collaboration and other revenue	1,545	1,598
Total revenues	57,336	32,607
Cost of goods sold
Cost of product and other revenue	7,625	2,594
Amortization of intangible asset	—	9,011
Total cost of goods sold	7,625	11,605
Operating expenses:
Research and development	9,754	9,731
Selling, general and administrative	25,742	25,438
License	701	711
Restructuring	—	58
Total operating expenses	36,197	35,938
Income (loss) from operations	13,514	(14,936)
Other income (expense)
Interest expense	(7,770)	(2,498)
Other income	213	95
Change in fair value of warrant liability	155	(129)
Loss on extinguishment of debt	—	(517)
Net income (loss) before income taxes	$6,112	$(17,985)
Net income (loss)	$6,112	$(17,985)
Comprehensive income (loss)	$6,112	$(17,985)
Net income (loss) per share:
Basic	$0.03	$(0.09)
Diluted	$0.03	$(0.09)
Weighted average common shares outstanding:
Basic	235,497,720	204,955,151
Diluted	241,602,853	204,955,151

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.